Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Safety User Fees Explored By Sen. Grassley In Questions For Crawford

Executive Summary

Senate Finance Committee Chairman Charles Grassley is interested in the idea of funding FDA's drug safety activities with user fees

You may also be interested in...



PDUFA IV Is “Golden Opportunity” To Improve Drug Safety Funding And Staff

The current round of reauthorization of the Prescription Drug User Fee Act presents a "golden opportunity" to improve FDA's regulation of drug safety, according to the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee

PDUFA IV Is “Golden Opportunity” To Improve Drug Safety Funding And Staff

The current round of reauthorization of the Prescription Drug User Fee Act presents a "golden opportunity" to improve FDA's regulation of drug safety, according to the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee

Drug Safety Bill Authorizes Fines On Industry, But Does Not Include User Fees

The Center for Postmarket Drug Evaluation & Research proposed in legislation from Sens. Grassley and Dodd would be funded by appropriations, not user fees

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS045529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel